Articles By Jack Cush, MD
RheumNow Podcast – DESIREABLE Results (5.3.19)
Dr. Jack Cush reviews the latest journal articles and rheumatology news from the past week on RheumNow.com:
Read Article
Nonadherence is Costly for Patients in Pain
A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs.
Read Article
Ideal Outcomes are Seldom Achieved in Gout
Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) 6 mg/dL and remission are rare, especially for those with severe gout.
Read Article
Omega-3 Rich Fish Lowers Gout Flares
Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.
Read Article
FDA Adds Boxed Warning to Sleep Drugs
The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not
Read Article
High GPA Hospital Readmission Rates
A national database reveals that patients with granulomatosis with polyangiitis (GPA) have 22.3% risk of hospital readmissions within 30 days of discharge. From a total of 9749 hospital admissions with GPA, there were 2173 readmissions within 30 days of discharge.
Read Article
New ACR/AF Guidelines on JIA Polyarthritis and Uveitis
The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA).
Read Article
RheumNow Podcast – Take it Back Jack! (4.26.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Naproxen has no Effect on Alzheimer's
A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).
Read Article
More Studies Needed to Optimize the Use of Osteoporosis Drugs
The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain. 
Read Article
